Still Seeking New Growth Areas, Cephalon Reassures Investors It Can Continue To Build Nuvigil And Treanda
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon highlighted the life-cycle management of its existing franchises during an R&D day held in New York on Nov. 18, with a focus on Nuvigil and Treanda.
You may also be interested in...
Cephalon’s Nuvigil For Jet Lag Is Pulled Off The Runway; Bipolar Indication Remains On The Horizon
After dropping efforts to obtain approval of Nuvigil (armodafinil) for treatment of jet lag disorder, Cephalon is left with one possible new indication for the wakefulness drug: depression associated with bipolar disorder.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.